A PPAR-gamma, egy lipidek által aktivált transzkripciós faktor aktivitásának szabályozása a makrofágok különböző állapotaiban  =  Regulation of the activity of a lipid-activated transcription factor, PPAR-gamma in macrophages by Szántó, Attila
OTKA 
Zárójelentés a 61814 azonosítójú, 
A PPAR-gamma, egy lipidek által aktivált transzkripciós faktor aktivitásának 
szabályozása a makrofágok különböző állapotaiban 
című pályázathoz 
 
Összefoglaló 
A Peroxisome Proliferator-activated Receptor γ (PPARγ) egy lipidek által aktivált 
transzkripciós faktor, mely a lipidanyagcsere és a gyulladás szabályozásával olyan 
folyamatokban vesz részt, mint az érelmeszesedés és diabétesz. A PPARγ aktivátorai 
több szinten képesek a gyulladás gátlására. Jelen pályázat célja az volt, hogy 
tanulmányozzuk a gyulladásos folyamatok PPARγ aktivitására kifejtett hatását, 
megvizsgáljuk, hogy a gyulladásos mediátorok hogyan kommunikálnak a PPARγ-val és 
megfejtsük ezeknek folyamatoknak a molekuláris mechanizmusát. Azt találtuk, hogy a 
gyulladásos molekulák befolyásolják a PPARγ működését. Proinflammatórikus 
molekulák gátolják, míg az interleukin-4 (IL-4) fokozza a receptor működését 
makrofágokban és dendritikus sejtekben. Az IL-4 szignálútvonal bekapcsolása egy 
újonnan feltárt mechanizmussal, a Signal Transducer and Activators of Transcription 6 
(STAT6) és a PPARγ interakciója révén erősíti a receptor válaszait a célgének 
promóterén. Ennek eredményeképpen az IL-4 emeli a PPARγ által szabályozott gének 
számát és fokozza az egyes gének esetében azok transzkripcióját. Ily módon a PPARγ 
egy pozitív transzkripciós faktorként működhet a makrofágokban is. Eredményeink 
szerint létezik egy új mechanizmus, ahogy az immunrendszer sejtspecifikusan képes 
 2 
szabályozni egy magreceptor működését. Mindez felhívja a figyelmet a sejtek 
gyulladásos állapota és a lipidanyagcsere kapcsolatára olyan folyamatokban, mint pl. az 
érelmeszesedés. 
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Részletes rész 
Mivel a pályázat legfőbb témájául szolgáló eredményeinket most rendezzük kézirattá 
ezért a legjobb összegzés ennek a kéziratnak a bemutatásával lehetséges. Ezt az 
alábbiakban tesszük meg a szöveg és az ábraanyag bemutatásával. 
Itt pedig a lefőbb kísérleti eredményeinket mutatjuk be: 
(1) A PPARγ expressziója nem mindig korrelál annak ligand általi aktiválhatóságával. 
(2) Gyulladásban szerepet játszó molekulák specifikusan és reverzibilisen befolyásolják 
mind a receptor kifejeződését, mind válaszkészségét a makrofágokban és a dendritikus 
sejtekben. 
(3) Proinflammatórikus molekulák gátolják, 
(4) míg a gyulladásgátló interleukin-4 (IL-4) fokozza a PPARγ expresszióját és 
aktivitását emberi és egér sejteken. 
(5) Az IL-4 kezelt alternatívan aktivált makrofágok és az éretlen dendritikus sejtek a két 
fő myeloid sejttípus, ahol a PPARγ funkcionális. 
(6) Globális génexpresszós analízissel meghatároztuk PPARγ által szabályozott géneket 
emberi és egér makrofágokban és kb. azonos számú gén indukálódik, mint amennyi 
represszálódik. 
(7) A PPARγ agonisták nem befolyásolják a makrofágok alternatív aktiválásra jellemző 
általános markereinek a szintjét és maga a receptor nem feltétlenül szükséges az 
alternatív aktiválás létrejöttéhez. 
(8) A receptor viszont képes olyan géneket indukálni, melyek egyébként az IL-4-nek is 
célpontjai és így a PPARγ képes befolyásolni az alternatív aktiválás lefolyását. 
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(9) Az IL-4 hatásmechanizmusát tanulmányozva megállapítottuk, hogy az IL-4 a Jak3-
STAT6 útvonalon keresztül fejti ki hatását a PPARγ-ra. A STAT6 szükségességét 
knockout egerekkel bizonyítottuk. 
(10) Más mechanizmusokat kizárva megmutattuk, hogy a STAT6 a PPARγ célgének 
promóterén hat, és 
(11) interakcióba lép a PPARγ-val, így engedélyezve a PPARγ célgének átíródását. 
(12) Bioinformatikai módszerekkel magasabb ggyakoriságot mutat a STAT kötőhely a 
PPARγ válaszadó elemek környékén, ami a microarray adatokkal együtt arra utal, hogy a 
STAT6 a myeloid sejtekben egy általános “licensing” faktor a PPARγ számára. 
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Abstract (max. 200 words) 
 
Peroxisome Proliferator-activated Receptor γ (PPARγ) is a lipid-activated transcription 
factor that regulates lipid metabolism and inflammation, key processes in atherosclerosis 
and diabetes. PPARγ agonists are known to regulate inflammation on multiple levels. 
However, it has been poorly studied how the inflammatory milieu regulates the activity 
of PPARγ and most of the known PPARγ target genes derived from the adipose tissue. 
We demonstrate here that inflammatory molecules interfere with PPARγ signaling. 
Proinflammatory molecules inhibit, while interleukin-4 (IL-4) stimulate PPARγ in 
macrophages and dendritic cells (DCs). Activation of IL-4 signaling augments PPARγ 
activity through a novel interaction between PPARγ and Signal Transducer and 
Activators of Transcription 6 on the promoter of PPARγ target genes, like FABP4. As a 
consequence, IL-4 strongly enhances PPARγ response and acts as a licensing factor by 
increasing the number of genes regulated and also the magnitude of the responses. 
Through target gene induction PPARγ can be designated a positive regulator of 
macrophage gene expression. These findings introduce a new mechanism how 
inflammatory molecules modulate the activity of a nuclear receptor via cell-type specific 
factors and highlight the importance of the inflammatory status of cells in lipid 
metabolism and atherosclerosis. 
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Introduction (max. 63000 characters) 
PPARγ is a member of the nuclear receptor superfamily, a group of ligand-activated 
transcription factors that regulate expression of their target genes upon ligand binding. 
For PPARγ oxidized fatty acids serve as endogenous activators {Kliewer, 1997 
#82}{Krey, 1997 #83}. PPARγ has been shown to regulate many aspects of lipid 
metabolism and inflammation. Major biological roles for the receptor include the 
differentiation of adipocytes {Tontonoz, 1994 #80} and the regulation of lipid/cholesterol 
metabolism in macrophages {Nagy, 1998 #5}{Ricote, 1998 #90}{Tontonoz, 1998 #81}. 
Macrophages are not a homogenous population. They originate from bone marrow 
progenitors committed to the monocytic lineage. The newly formed monocytes are 
released into the circulation then enter the tissues to differentiate into mature resident 
macrophages. Alternatively, under inflammatory conditions monocytes themselves are 
recruited to sites of inflammation. Initially, activated macrophages were defined as 
cytokine producing inflammatory cells that are able to kill pathogens. However, the 
immunophenotype and function of these cells depend on the environment and presence of 
various activator molecules {Gordon, 2003 #50}. Macrophages not only mediate 
pathogen clearance but act as also key regulators of the resolution after inflammation. 
Both activities are driven by cytokines and microbial products and manifested in forms of 
distinct activation states {Ma, 2003 #93}. 
Proinflammatory molecules like interferon γ (IFNγ) and tumor necrosis factor (TNF) or 
activators of pattern recognition molecules (e.g. Toll-like receptors (TLRs)) result in 
classical activation of macrophages. Consequently, macrophages migrate to the sites of 
inflammation and degrade pathogens due to increased production of nitrogen radicals and 
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secretion of proinflammatory molecules such as TNF, IL-1 and IL-6. The classical 
pathway of IFNγ-dependent activation of macrophages by Th1-type responses is a well-
established arm of the cellular innate immunity directed against intracellular pathogens 
like Listeria monocytogenes or Mycobacterium tuberculosis {Goerdt, 1999 #37}{Mosser, 
2003 #35}. 
As part of their studies on the regulation of mannose receptor Gordon and colleagues 
identified a new class of macrophages, the so-called alternatively activated macrophages 
that in contrast to the classically activated ones express high level of mannose receptor 
upon IL-4 stimulus {Stein, 1992 #31}. These cells exert an almost opposite phenotype as 
their classically activated counterparts. They cannot produce nitrogen-monoxide, able to 
inhibit T cell proliferation {Schebesch, 1997 #34} and can provoke tolerance or Th2 
immune responses {Cua, 1997 #38}. These cells also produce transforming growth factor 
β (TGFβ), IL-10, IL-1 receptor antagonist {Goerdt, 1999 #37}{Schebesch, 1997 
#34}{Fenton, 1992 #42} and inhibit secretion of proinflammatory molecules, like IL-1, 
TNF, IL-6, IL-12 and macrophage inhibitory protein (MIP)-1α {Cheung, 1990 
#43}{Standiford, 1993 #44}{Bonder, 1998 #45}. Alternatively activated macrophages 
are characterized by the expression of mannose receptor {Stein, 1992 #31}, CD23 
{Becker, 1990 #68}, alternative macrophage activation-associated chemokine 1 (AMAC-
1 or CCL18) {Kodelja, 1998 #32}, arginase-1 {Munder, 1999 #69}, FIZZ1 and YM1 
{Raes, 2002 #33}. The alternative activation of macrophages by Th2 cytokines IL-4 and 
IL-13 accounts for a distinct macrophage phenotype playing role in humoral immunity 
and various processes during resolution: wound healing, angiogenesis, tissue repair and 
extracellular matrix deposition {Goerdt, 1993 #46}{Kodelja, 1997 #53}{Kodelja, 1998 
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#32}{Gratchev, 2001 #36}{Gordon, 2003 #50}{Mosser, 2003 #35}. Under normal 
conditions characteristic in vivo examples for alternatively activated macrophages are 
lung alveolar macrophages, perivascular and placenta macrophages {Mues, 1989 
#39}{Chang, 1993 #47}{Kodelja, 1998 #32}{Linehan, 1999 #54}{Fabriek, 2005 #62}. 
Several lines of evidence indicate the existence of a crosstalk between lipid metabolism 
and inflammation. Obesity is now considered to be an inflammatory disorder 
accompanied by the accumulation of macrophages {Weisberg, 2003 #104}{Xu, 2003 
#105}{Kanda, 2006 #106}{Kamei, 2006 #107}. Two nuclear receptors PPARγ and Liver 
X Receptor (LXR) have been shown to play pivotal roles in the communication between 
lipid metabolism and the immune system. Such communication channel could be 
bidirectional, however in case of PPARγ only one way (from the lipid metabolism to the 
immune system) has been tested mechanistically so far. Activators of PPARγ like the 
prostanoid, 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) {Forman, 1995 #84}{Kliewer, 
1995 #85} or the synthetic anti-diabetic agent thiazolidinedions (TZDs) {Lehmann, 1995 
#89} have been shown to inhibit inflammation under certain conditions. Most of our 
knowledge about the role of PPARγ in inflammation is based on a special inflammatory 
cell type with largely unknown characteristics; murine thioglycolate-elicited peritoneal 
macrophages treated with various synthetic agonists and/or proinflammatory molecules. 
Several reports described PPARγ as a negative regulator of macrophage activation, based 
on data showing that PPARγ agonists inhibited the expression of proinflammatory 
molecules, like inducible nitric oxide synthase, gelatinase B, TNF, IL-1β, IL-6 and IL-12 
{Jiang, 1998 #18}{Ricote, 1998 #17}{Alleva, 2002 #26}. Importantly, the negative 
regulatory role assigned to PPARγ was not a direct transcriptional effect of the receptor 
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but the consequence of the failed induction of inflammatory genes by other transcription 
factors activated upon proinflammatory molecules e.g. lipopolysaccharide (LPS) {Li, 
2000 #91}{Pascual, 2006 #92}. The molecular mechanism, how PPARγ activators exert 
their anti-inflammatory effects is still controversial. Some of these were reported to be 
nonspecific, PPARγ-independent effects of the agonists, due to the facts that some of the 
anti-inflammatory reactions exist in the absence of the receptor and/or these function at 
higher ligand concentrations than necessary for receptor specific transcriptional 
activation {Chawla, 2001 #22}. One possible molecular mechanism for the trans-
repression of other transcription factors by PPARγ was suggested by Pascual et al., which 
involves ligand-dependent sumoylation of the receptor targeting it to corepressor 
complexes. This process prevents recruitment of proteosome machinery that normally 
removes the corepressor complexes required for gene activation {Pascual, 2005 #28}. 
Surprisingly, only a few positively regulated genes of PARγ have been identified in the 
murine macrophages {Welch, 2003 #27}, while PPARγ seems to induce and repress 
euqal number of genes in human dendritic cells (DCs), a macrophage-related cell type 
{Szatmari, 2007 #71}. According to these PPARγ responses are considered to be cell-
type specific: in murine macrophages it can inhibit proinflammatory gene expression 
while in adipocytes and human DCs it can induce transcription of lipid metabolism-
related genes and no certainties are known about human macrophages. The mechanism of 
these cell-type specific responses is largely unknown. 
Recently, LXR, another member of the nuclear receptor superfamily and target for 
PPARγ {Chawla, 2001 #6} was also shown to play important role in the communication 
between lipid signals and the immune system. Activation of LXR results in the inhibition 
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of inflammatory gene expression in macrophages {Joseph, 2003 #64} and also impacts 
anti-microbial responses {Joseph, 2004 #100}{Valledor, 2004 #101}. Proinflammatory 
molecules, bacteria and viral compounds via interferon regulatory factor 3 could inhibit 
LXR-dependent transcriptional activity {Castrillo, 2003 #63}. PPARγ and LXR share 
many common features {Torocsik, 2009 #103}. The two receptors work together in the 
regulation of cholesterol metabolism in macrophages {Nagy, 1998 #5}{Tontonoz, 1998 
#81}{Chawla, 2001 #6}. A mechanism similar to PPARγ was suggested for the 
inhibition of proinflammatory target gene expression by LXR {Ghisletti, 2007 #102}. 
However, the other direction of the hypothesized bidirectional crosstalk between lipid 
metabolism and inflammation, namely the influence of immune modulators on PPARγ 
has not yet been analyzed systematically. 
There are hints in the literature that such influence exists. In adipose tissue PPARγ could 
be inhibited by phosphorylation via mitogen-activated protein (MAP) kinase {Hu, 1996 
#76}{Adams, 1997 #77}. In mouse adipocytes IFNγ induces rapid proteasomal 
degradation of the receptor {Waite, 2001 #23}. Furthermore, IL-1 and TNF inhibit 
adipogenesis through nuclear factor κB (NF-κB)-dependent inhibition of PPARγ DNA 
binding capacity {Suzawa, 2003 #25}. It was also shown previously that IL-4 induced 
PPARγ and ligand production for the receptor in murine macrophages {Huang, 1999 
#19}. However, there is inconclusiveness around PPARγ requirement for alternative 
macrophage activation. PPARγ was first reported to be required for maturation of 
alternatively activated macrophages and disruption of the gene impaired alternative 
macrophage activation in mouse {Odegaard, 2007 #70} while later others in another 
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mouse strain claimed the dispensability of PPARγ for alternative activation {Marathe, 
2009 #111}. Nevertheless, no mechanism of such involvement has been suggested. 
Although PPARγ has been studied in many reports, it has been analyzed regardless of the 
inflammatory status of the cells. Besides the trans-repression no effort has been made to 
find the mechanism of the crosstalk how inflammatory mediators influence ligand-
induced transcriptional activity of PPARγ in inflammatory cells like macrophages and 
DCs. However, that could reveal the cell-type specific differences in receptor-evoked 
responses. 
It has not been clarified so far if proinflammatory mediators influence PPARγ expression 
and/or responses in the macrophages like they do in adipocytes or in case of LXR. It has 
not been defined in which subpopulation of the macrophages PPARγ is predominantly 
expressed and functional. So we sought to define such cell-types and determine the 
molecular mechanism, which makes one cell different from another concerning PPARγ 
expression and ligand-induced transcriptional activation and wanted to characterize the 
conditions and permissive factors that besides the receptor level and ligand availability 
determine PPARγ responses. 
In the work presented here we found that (1) expression of the receptor do not always 
correlate with its ligand-induced transcriptional activity, (2) many inflammatory 
molecules interfere with PPARγ signaling and the activation type of the 
macrophages/DCs definitely but reversibly determines PPARγ activity, (3) 
proinflammatory molecules inhibit, while (4) IL-4 stimulates PPARγ expression and 
ligand-induced transcriptional activity in human as well as in murine macrophages and 
DCs, (5) alternatively activated macrophages and immature DCs are the particular cell 
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types where PPARγ could be functional, while under inflammatory conditions in 
classically activated macrophages PPARγ response is inhibited. (6) By transcriptional 
profiling PPARγ was found to induce and repress approximately equal number of genes 
both in human and mouse alternatively activated macrophages. (7) By an unbiased 
approach general PPARγ activity was concluded to depend on the presence of IL-4 in 
myeloid cells. (8) PPARγ agonists do not alter the expression of known markers for 
alternative macrophage activation and PPARγ is dispensable for this process. (9) The 
receptor through its target genes acts as a modifier of the alternative activation program 
since many PPARγ-induced genes are also targets for the IL-4 per se. We analyzed the 
mechanism that makes these two cell types permissive for PPARγ activation and provide 
a novel molecular mechanism. (10) IL-4 activated Signal Transducer and Activators of 
Transcription 6 (STAT6) is a determinant factor for PPARγ responses in macrophages 
and DCs. (11) STAT6 interacts with PPARγ on the promoter of target genes and 
consequently activates PPARγ and license ligand-induced transcription. (12) Frequency 
of STAT binding sites in the proximity of PPARγ response elements is increased. With 
our findings we introduce a new mechanism how inflammatory molecules can determine 
the activity of a nuclear receptor and highlight the importance of signaling crosstalk and 
composite gene expression regulation. 
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Results 
 
Expression and ligand-induced transcriptional activity of PPARγ depends on the 
activation state of macrophages and DCs 
In order to highlight the differences in the expression and activity of PPARγ in myeloid 
cells we sought to systematically characterize how various inflammatory stimuli 
influence PPARγ expression and activity in macrophages and DCs. First, we purified 
human CD14 positive monocytes and cultured them in vitro to obtain monocyte-derived 
macrophages and immature DCs. As a model for macrophage activation we used IL-4 to 
alternatively activate macrophages and proinflammatory molecules (IFNγ, TNF and LPS) 
to induce classical activation of macrophages or to induce the maturation of DCs. Under 
these conditions CD206, CD209, CD23 and AMAC-1 were induced upon alternative 
activation while CD80, CD83, CD86 and HLA-DR were upregulated by classical 
activation and CD1a, CD209 were used as markers of DC development (data not shown). 
First, we analyzed the expression and ligand-induced transcriptional activity of PPARγ in 
this in vitro model of macrophage and DC development. As shown in Figure 1A PPARγ 
is expressed in the monocytes at a low level, which is induced in the macrophages. 
Interestingly, IL-4 further increased PPARγ expression, while IFNγ resulted in a 
decreased expression. In human macrophages we found that LPS and granulocyte-
monocyte colony stimulating factor (GM-CSF) also induced the receptor level. In 
immature DCs differentiated with GM-CSF and IL-4 we measured high PPARγ 
expression, which was slightly induced upon maturation. Given the expression pattern of 
PPARγ under the tested conditions we next compared the activity of the receptor by 
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adding PPARγ specific synthetic agonist, Rosiglitazone (RSG). To follow PPARγ activity 
we chose the most specific known PPARγ target gene, fatty acid binding protein 4 
(FABP4 or aP2) {Tontonoz, 1994 #80}. When measuring FABP4 mRNA levels we 
obtained dramatic differences (Figure 1B). Under two conditions FABP4 was strikingly 
induced: in the IL-treated alternatively activated macrophages and in the GM-CSF+IL-4 
treated immature DCs. Only slight induction could be observed in the non-activated 
macrophages and in the IL-4-treated macrophages in the absence of RSG, which resulted 
in a comparable level as RSG-treated non-activated macrophages. Additionally, IFNγ, 
IFNγ+TNF and LPS inhibited target gene induction in macrophages and LPS also 
inhibited FABP4 expression in the mature DCs. We used Listeria monocytogenes as a 
biologically relevant pathogen and found that the bacteria did not change the expression 
of PPARγ but did inhibit its activity similarly as LPS (data not shown). As a conclusion 
we got marked differences in the expression and activity of PPARγ. IFNγ reduced the 
expression of the receptor and also inhibited target gene expression. While LPS slightly 
increased receptor level it inhibited the activity. IL-4 induced expression of the receptor 
and it also enhanced ligand-induced transcriptional activity of the receptor. Since the 
expression of the receptor did not correlate with activity at multiple levels, i.e. LPS or 
GM-CSF did not results in elevated target gene expression and the degree of target gene 
induction in the IL-4-activated cells exceeded that could be explained by the PPARγ 
levels we hypothesized that not only the level of PPARγ but also its activity might be 
under control by the IL-4. We named this phenomenon IL-4-induced augmented PPARγ 
response and tested if such IL-4-induced mechanism could be responsible for the cell-
type specific differences in PPARγ responses. 
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We compared the expression of other PPARs in the monocytes, non-activated and 
activated macrophages. We found that both PPARα and PPARδ are induced during 
macrophage development but with weaker dynamic (Supplementary Figure 1A and C) 
than PPARγ (Supplementary Figure 1D). Although PPARα and δ were induced no 
differences in their levels upon macrophage activation were found (Supplementary Figure 
1A and C), while PPARγ showed two fast effects (Supplementary Figure 1B): first it was 
rapidly induced by the monocyte-macrophage transition and simultaneously IL-4 could 
further increase its level. IFNγ+TNF treatment caused a delayed repression of the 
transcript level. When comparing the expression of the three PPARs in the non-activated 
macrophages all PPARs are present, while in the alternatively activated macrophages 
PPARγ is the dominant isoform and it is missing in the classically activated cells 
(Supplementary Figure 1E). Since PPARγ and LXR have been involved in many 
commonly regulated processes we compared the expression of LXRα to PPARγ and 
surprisingly we could detect an inverse regulation (Supplementary Figure 1D). LXRα is 
induced upon macrophage development but much slower than PPARs and IFNγ+TNF 
could further increase its transcription. 
Next, we performed immunohistochemistry on primary macrophages to analyze the 
protein levels of PPARγ. As shown in Figure 1C consistently with the mRNA results 
PPARγ protein is expressed at highest level in the IL-4-treated cells (brown nuclear 
staining), less positive nuclei could be seen in the non-activated cells and IFNγ+TNF 
treatment resulted in the lowest PPARγ expression (Figure 1C). Figure 1D indicates the 
expression of FABP4 protein in macrophages under the different activation states. 
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FABP4 induction was detected only in the alternatively activated macrophages upon 
RSG treatment correlating with the mRNA levels in Figure 1B. 
In order to assess the in vivo expression pattern and distribution of PPARγ positive 
macrophages we carried out a systematic survey using immunohistochemistry. We 
analyzed human lymphoid tissues such as Peyer’s patches, lamina propria of the 
intestinal vili, reactive lymph nodes, tonsils and known areas of alternatively activated 
macrophages (Supplementary Figure 2). We used CD68 as a general macrophage and 
DC-SIGN as a specific and selective marker for alternatively activated macrophages 
and/or DCs {Geijtenbeek, 2000 #65}, {Relloso, 2002 #66}. The conclusion of our 
analysis indicated that (1) PPARγ was not expressed in every CD68 positive macrophage, 
(2) PPARγ positive macrophages were not necessarily DC-SIGN positive, but (3) almost 
every DC-SIGN positive macrophage expressed PPARγ. (4) PPARγ expressing 
macrophages were localized in preferential compartments of the lymphoid organs, mainly 
around the germinal centers in the perifollicular T-cell areas. PPARγ co-localized with 
DC-SIGN very prominently in perivascular and alveolar macrophages. 
We examined if PPARγ responses differ under various activation stimuli when natural 
sources of ligands such as oxLDL is used. oxLDL had similar effects to RSG on FABP4 
gene expression and IL-4 increased the effects of oxLDL similarly to RSG (Figure 1E). 
We wanted to see if the explored pathways were restricted to only human monocyte-
derived cells. First, we isolated human CD34 positive stem cells and differentiated them 
to macrophages in vitro. After 9 days of maturation we induced activation by IL-4 or 
IFNγ+TNF. When treating with RSR we obtained similar results as in monocyte-derived 
macrophages: a moderate induction in the non-activated cells, a large induction in the IL-
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4-treated cells while no response was detected in the classically activated macrophages 
(Figure 1F). 
 
PPARγ  responsiveness is reversibly and dynamically changing 
Based on our data we hypothesized that the activation state-modulated PPARγ activity of 
macrophages is not an irreversible end-stage but the result of the changing cytokine 
environment. To evaluate this scenario we performed sequential treatments: pretreated 
the macrophages with one cytokine for 6 hours and then added the second cytokine. After 
6 hours the cells were treated with vehicle or RSG for an additional 6 hours (Figure 1G 
and H). Expression of PPARγ changed reversibly upon macrophage activation (Figure 
1G). On one hand PPARγ could be repressed by IFNγ+TNF after IL-4 pretreatment, on 
the other hand PPARγ could be induced by IL-4 in the IFNγ+TNF pretreated cells (Figure 
1G arrows). Looking at PPARγ responsiveness, IFNγ+TNF repressed PPARγ activity in 
the IL-4 pretreated macrophages while IL-4 induced PPARγ activity in the IFNγ+TNF 
pretreated cells (Figure 1H arrows). These data suggest that PPARγ expression and 
activity is reversibly and could be dynamically regulated by the cytokine milieu. 
We analyzed the specificity of the inflammation-induced changes in PPARγ responses by 
examining other targets for the receptor and other nuclear receptors. PPARα signaling 
did not prove to be very active in macrophages, which could be explained probably by 
the low expression of the receptor and/or tissues specific factors (data not shown). Both 
PPARγ and δ agonists induced adipose differentiation-related protein (ADRP), however 
IL-4 could enhance only the effect of the PPARγ agonist but had no effect on PPARδ 
(Supplementary Figure 1F). PPARδ response was inhibited only by IFNγ, to a lesser 
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extent by LPS (TLR4), Lipid A (TLR4) or L. monocytogenes but not by LTA (TLR2), 
PolyI:C (TLR3) or CpG (TLR9) treatment (Supplementary Figure 1F). LXR activity did 
not seem to be fundamentally affected by the activation state of the macrophages as 
analyzed by the induction of its target genes ABCA1, ABCG1 and LXRα (data not 
shown). We found only a moderate inhibition with TLR3 and TLR4 activators, similarly 
as reported previously on murine macrophages {Castrillo, 2003 #63}. Based on these 
results we concluded that IL-4-induced augmented response is true for PPARγ induced 
genes and also for an RAR target gene, but not for PPARδ or LXR. Inducers of classical 
activation eliminated PPARγ activity but had no or moderate effects on PPARδ, while 
inhibited LXR target gene expression accordingly to the literature. 
 
IL-4 induces augmented PPARγ  response in mouse macrophages 
We analyzed if our findings are specific for human cells or similar regulation exists in 
murine macrophages as well. First, we studied C57Black/6 wild type mice. We isolated 
monocytes from the bone marrow and cultured them in the presence of IL-4 or 
IFNγ+TNF. Consistently to our results in the human cells the expression of PPARγ was 
increased by IL-4 and repressed by IFNγ+TNF (Figure 2A). By adding RSG PPARγ 
could activate gene expression of FABP4 (Figure 2B) and ADRP (Figure 2C) in the non-
activated and in the alternatively activated cells but not in the classically activated ones. 
IL-4 per se could induce the expression of both target genes and similarly to the human 
macrophages increased ligand-induced PPARγ response. Next, we used thioglycolate-
elicited peritoneal and bone marrow-derived macrophages and activated them with IL-4, 
IFNγ+TNF or LPS, respectively. We analyzed the expression of known murine markers 
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of macrophage activation (Supplementary Figure 3A-L). IL-4 induced the expression of 
FIZZ1, mannose receptor (MR), YM1, arginase 1 (Arg1) and PPARγ while IFNγ+TNF 
and LPS increased the level of inducible nitrogen-oxide synthetase (iNOS) in both 
peritoneal and bone marrow-derived macrophages. 
Then, we treated bone marrow-derived macrophages and DCs with RSG to assess PPARγ 
activity. In Figure 2D RSG was added throughout the differentiation of DCs (Day1) or 
later as indicated. Interestingly, the mRNA level of the PPARγ target gene changed upon 
the time when the ligand was added. It seemed that PPARγ activator should be present 
from the beginning of the differentiation process to obtain maximal induction. However, 
a smaller response was still present when added on the 8th day. When comparing the 
levels of FABP4 in the immature and mature DCs there was a remarked repression of 
gene expression, which required only one day to almost completely eliminate the 
induction of the target gene (compare immature-mature Day1 values). 
In case of the bone marrow-differentiated macrophages we observed a clear difference to 
the human cells (Figure 2E). The basal expression level of the FABP4 was higher than in 
the human macrophages. Probably due to this fact the dynamic range for the induction is 
narrower. Nevertheless, RSG could induce FABP4 more efficiently when added earlier. 
IL-4 could induce augmented PPARγ response at every time point examined (Figure 2E). 
IFNγ+TNF repressed PPARγ activity independently of the time, while LPS was more 
active when added later (Figure 2E). 
To further examine the potential of PPARγ to activate target gene expression in murine 
cells we compared the inducibility of three PPARγ-regulated genes in bone marrow-
derived DCs (Figure 2F, H and J) and macrophages (Figure 2G, I and K): PPARγ 
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Angiopoietin-related Protein (PGAR) (Figure 2F and G) FABP4 (Figure 2H and I) and 
ADRP (Figure 2J and K). All of them were induced in immature DCs and also in 
alternatively activated macrophages upon ligand treatment. We also compared PPARα, γ 
and δ agonists and found that the effects of RSG were impaired by IFNγ, TNF and LPS, 
while PPARδ agonist still induced ADRP expression in the TNF or LPS-treated cells 
(data not shown). With these findings we demonstrated that PPARγ can be activated in 
murine cells (macrophages and DCs), which in turn could induce transcription of target 
genes. We recognized the importance of the optimal conditions: time and length of ligand 
treatment, presence of IL-4 and absence of proinflammatory cytokines, bacterial 
compounds. The major difference in our experiments compared to others’ where only a 
few genes were induced by the receptor {Welch, 2003 #27} was that we added the 
cytokines and the ligands during the whole differentiation process. We assume that 
during the differentiation a slightly different cell type is formed in the presence of IL-4, 
which is capable of responding to PPARγ activators. 
 
Identification of PPARγ-regulated transcripts in murine macrophages and DCs 
In order to further investigate PPARγ as a positive regulator of gene expression in murine 
cells we decided to perform microarray experiments and determine PPARγ-regulated 
genes in the two permissive cell types, alternatively activated macrophages and DCs. To 
discover PPARγ-specific targets in murine macrophages and DCs we used conditional 
knockout mice. To induce macrophage-specific recombination we chose the Lysozyme 
Cre-PPARγ lox system. Lysozyme Cre positive PPARγ+/+ mice were used as controls. 
The degree of recombination was assessed by detecting the wild type and truncated 
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mRNAs in Supplementary Figure 4A. We analyzed the expression of PPARγ and its 
target genes in peritoneal macrophages and bone marrow-derived macrophages or DCs 
(Supplementary Figure 4B and C). PPARγ was induced by IL-4 in both the alternatively 
activated macrophages and during DC development, while IFNγ, TNF or LPS repressed 
it. FABP4 mRNA level was slightly increased in the wild type non-activated 
macrophages upon RSG treatment, which was remarkably increased by IL-4 and 
repressed by IFNγ. When comparing Lysozyme Cre positive PPARγ+/+ and PPARγfl/fl 
mice we could still detect the induction of PPARγ target gene at comparable levels as in 
the PPARγ+/- animals. RSG-induced target gene expression was completely absent in both 
alternatively activated macrophages and DCs only in the PPARγfl/- mice suggesting that 
the recombination was more effective in mice with only one PPARγ floxed allele. Similar 
results were obtained in peritoneal macrophages (Supplementary Figure 4C). 
Next, we performed a microarray experiment and compared the expression of RSG-
regulated genes in bone marrow-derived macrophages and DCs from Lysozyme Cre 
positive PPARγ+/- (control group) and PPARγfl/- animals (conditional knockout group). 
Agreeably to our observations we could identify 764 gene probes in DCs and 683 genes 
probes in alternatively activated macrophages being significantly (p<0.05, Benjamini 
multiple testing correction) regulated at least two-fold by RSG in the +/- but not in fl/- 
animals based on 4 biological replicates (Supplementary Table 1). From these 416 gene 
probes were upregulated and 348 were repressed in DCs and 330 gene probes were 
induced while 353 were downregulated in macrophages. These numbers indicate that 
under these conditions PPARγ can regulate approximately similar number of genes in 
both cell types and in both directions and more importantly suggest that under these 
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circumstances the receptor can function as a transcription factor observed in human DCs 
previously {Szatmari, 2007 #71} or in human macrophages (see below). 
 
PPARγ  is dispensable for alternative macrophage activation 
There is a clear difference in the polarization of immune responses in the various mouse 
strains. C57Black/6 mice are prone to TH1 while BALB/c mice are prone to TH2 immune 
responses. Therefore, we compared if PPARγ could be induced by IL-4 in both mouse 
strains and found that like other markers of alternative macrophage activation like YM1, 
Arg1 or FIZZ1 PPARγ could be induced by IL-4 independently to the strain (Figure 4C-
J). We also treated these bone marrow-derived macrophages with vehicle or RSG, 
respectively and importantly we could not detect any consistent effects of PPARγ 
activation on the expression levels of alternative macrophage markers (Figure 4C-E and 
G-H). To further prove that PPARγ is dispensable for alternative macrophage activation 
we used macrophage-specific PPARγ conditional knockout animals on C57Black/6 
background and analyzed the induction of markers in peritoneal and bone marrow-
derived macrophages (Figure 4K and L). As it is clearly indicated in the figures both 
Arg1 and YM1 were induced by IL-4 in both macrophages independently of the presence 
of PPARγ. We should note that the expression of these molecules largely depend on IL-4. 
Without IL-4 their expression is almost completely shut down and upon IL-4 they are 
induced rapidly to very high levels. These data indicate that unlike a previous report 
{Odegaard, 2007 #70} PPARγ is dispensable for alternative macrophage activation. 
Furthermore, we found that IL-4 is required for the induction of the receptor and more 
importantly to attain maximum receptor activity. 
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IL-4 is a general intensifier of PPARγ  
After systematically characterizing the activity of PPARγ in human and murine 
macrophages and DCs we sought to identify the mechanism, how IL-4 activates PPARγ. 
First, we determined how important this phenomenon is in the general activation of the 
receptor. To study this we chose an unbiased approach and performed microarray 
experiments in human differently activated macrophages. We used non-activated, IL-4-
treated and IFNγ+TNF-treated macrophages and analyzed PPARγ-regulated global gene 
expression changes after RSG administration (Figure 5). The results of the microarray 
analysis explicitly showed that IL-4 influenced PPARγ-regulated gene expression on two 
levels: it made PPARγ regulate a larger set of genes (Figure 5A) and simultaneously 
intensified the changes in the individual transcript levels (Figure 5B and Supplementary 
Table 2). Strikingly, without macrophage activation 120 genes were regulated, which was 
increased to 624 in the presence of IL-4 and decreased to 63 during classical activation. 
Interestingly, we identified an interesting correlation between PPARγ-regulated genes 
and macrophage activation-regulated genes (Figure 5C-F). Most of the PPARγ-induced 
genes could be also upregulated by IL-4 or downregulated by classical activation (Figure 
5C 379 vs. 45 and Figure 5E 128 vs. 54). Generally, PPARγ-repressed genes could be 
also downregulated by IL-4 (Figure 5D and F). Here, we have to note that a larger set of 
PPARγ-repressed genes was downregulated than induced by classical activation (Figure 
5D and E). A more detailed comparison is available in Supplementary Figure 8. With 
such correlation between PPARγ and activation-regulated genes it became clear that not 
only IL-4 activates and enhances PPARγ signaling but also PPARγ can consequently 
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regulate genes involved in the activation processes, which subsequently leads to a more 
characteristic alternative activation pattern. This is a novel crosstalk between PPARγ and 
macrophage activation and also suggests a new mechanism for the anti-inflammatory 
effects of PPARγ: the receptor induces directly its target genes, which are also targets for 
IL-4, which is anti-inflammatory. And similar regulation might be true for the PPARγ-
repressed genes. 
 
IL-4 acts through STAT6 to activate PPARγ  
Classically IL-4 binds to its high-affinity receptor IL-4 receptor α chain {Cabrillat, 1987 
#94}{Park, 1987 #95}, which in turn forms a heterodimer with IL-2 receptor common γ 
chain in hematopoietic cells. IL-4 induces tyrosine phosphorylation of the receptor 
through recruitment of a Janus tyrosine kinase (JAK). Most commonly tyrosine 
phosphorylation of JAK3 occurs in response to IL-4 in myeloid cells {Witthuhn, 1994 
#98}. That could subsequently activate further proteins like STAT6 and insulin receptor 
substrate-2 (IRS-2) {Welham, 1995 #96}. Phosphorylated STAT6 forms homodimer, 
enters the nucleus and binds to DNA acting as a transcription factor. IRS-2 can activate 
src homology 2 (SH2) domain of proteins, most importantly in this case phosphoinsitol-2 
kinase (PI3 kinase) {Izuhara, 1996 #97}. 
According to these we wanted to address if IL-4 acts through the classical cytokine 
signaling via STAT6 to activate PPARγ or signals through SH2 domain binding proteins. 
To define the signaling pathway we used mice deficient in STAT6 and differentiated 
macrophages from bone marrow. In Figure 6A-C we show that IL-4 dependent induction 
of alternative activation markers FIZZ1 and YM1 and also that of PPARγ required the 
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presence of STAT6 because no induction could be detected in STAT6 knockout animals. 
The IL-4 induced activation of PPARγ was tested by adding RSG to the cells and PPARγ 
target genes’ expression levels were measured (Figure 6D-F). While RSG could slightly 
induce target gene expression in non-activated macrophages independently to the 
presence of STAT6, IL-4 induced PPARγ activation after RSG treatment was almost 
completely missing from STAT6 knockout mice referring to the requirement of STAT6 
to this phenomenon. 
We also used JAK inhibitors and PI3 kinase inhibitor in human macrophages. WHI-P131 
is a JAK3 inhibitor, while TYRPhostin (or AG490) is more specific for JAK2. 
Wortmannin was used to inhibit PI3 kinase. The induction of AMAC1, a known IL-4 
regulated gene was inhibited by JAK3 inhibitor, while JAK2 and PI3 kinase inhibitors 
did not inhibit its transcription by IL-4 (Figure 6G). Expression of PPARγ was induced 
by IL-4 and this induction was inhibited with WHI-P131 but not with Wortmannin 
(Figure 6H). JAK2 inhibitor increased PPARγ mRNA levels probably via an unknown 
mechanism. Next, FABP4 was induced by RSG and this induction was further increased 
in the presence of IL-4 as detailed above (Figure 6I). This IL-4 induced increase was 
absolutely abolished by the JAK3 inhibitor, WHI-P131, while neither the JAK2 not the 
PI3 kinase inhibitor affected this. These results are in agreement with the literature where 
JAK3 was claimed as a dominant JAK kinase in myeloid cells {Witthuhn, 1994 #98}. 
With data from the STAT6 knockout mice and the pharmacological characterization we 
can conclude that IL-4 acts via JAK3 and STAT6 to increase PPARγ activity and 
responses. 
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STAT6 activates PPARγ  on the promoter of PPARγ  target genes 
After concluding that IL-4 acts through STAT6 to activate PPARγ we took several 
possible mechanisms into consideration and experimentally tested them. In 
Supplementary Figure 8 we tested if STAT6 induced the production of a PPARγ agonist, 
which somehow overwrites the effects of RSG. IL-4 was shown to increase the 
production of a PPARγ activator, 15d-PGJ2 via inducing 12/15-lipoxygenase {Huang, 
1999 #19}. A possible mechanism could be the recently reported covalent binding of 
such or similar ligands {Itoh, 2008 #99}. By showing that IL-4 augmented PPARγ 
response well before the induction of 15-lipoxygenase in human macrophages we 
excluded that possibility (Supplementary Figure 9 A and B). We also excluded that 
STAT6 would generate an activator for the Retinoid X Receptor, the permissive 
dimerization partner for the PPARγ by using RXR antagonist (Supplementary Figure 
9C). Next, we tested if STAT6 induces histone acetylation and consequently opening of 
the chromatin making it easier accessible for PPARγ. We used trichostatin A, an inhibitor 
of histone deacetylases but no difference could be observed in the non-activated cells 
suggesting that the histone tails are not deacetylated and chromatin is not closed in the 
absence of IL-4 (Supplementary Figure 9D and E). Further possible mechanism could be 
that STAT6 induces the degradation of a repressor for PPARγ. We addressed this by 
using proteasome inhibitor, MG132 (Figure 6 G-I) but IL-4 still improved PPARγ 
response in the presence of the proteasome inhibitor. We addressed the opposite scenario 
as well: induction of an activator and or PPARγ itself. We showed that IL-4 could 
increase PPARγ mRNA level (Figure 1A). Although, we illustrated that the activity of 
PPARγ concerning target gene induction did not correlate with the expression level of the 
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receptor (Figure 1) we tested this scenario by inhibiting new protein synthesis by 
cycloheximide (CXM) (Supplementary Figure 9F-H). The expression of a STAT6-
regulated gene, AMAC1 and that of PPARγ were induced by IL-4, indicating the direct 
transcriptional event. Obviously, RSG could activate PPARγ independently of new 
protein synthesis. And IL-4 could still promote the effects of the PPARγ activator, 
indicating that the STAT-6-augmented PPARγ response did not require new protein 
synthesis. However, IL-4 could ameliorate PPARγ response, a slight decrease could be 
observed generally in the mRNA levels of FABP4, which could be due to the impaired 
production of PPARγ protein after IL-4 treatment. With this experiment we could 
dissociate the double effect of IL-4 on PPARγ: induction of the receptor and 
improvement of its responses. The first by definition depends on the protein synthesis but 
it is dispensable for the second. 
To add further evidence that STAT-6 improves PPARγ responses independently of the 
receptor level we used transiently transfected cells overexpressing PPARγ by a 
constitutively active cytomegalovirus promoter. In these cells PPARγ target gene 
expression could be enhanced by STAT6 when cotransfected and activated by IL-4 
(Supplementary Figure 9I). 
 
STAT6 interferes with PPARγ signaling on the transcription level 
From these data we could conclude that STAT6 presumably acts on the promoter of 
PPARγ target genes and interferes with PPARγ signaling at the transcription level. We 
tested the interaction of PPARγ with corepressors and coactivators in mammalian two-
hybrid experiments but IL-4 or STAT6 did not influence that interaction (data not 
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shown). To study PPARγ response on the promoter of its target genes we chose the 
promoter of the previously analyzed PPARγ target gene, FABP4. We isolated a 5-
kilobase (kb) fragment of the FABP4 promoter and studied in a reporter assay. The 5kb 
fragment responded to PPARγ activators and also to IL-4 (Figure 7A and B). Moreover, 
IL-4 could augment the effect of RSG consistently to the endogenous response of the 
target gene (Figure 7A and B). As part of the promoter analysis we generated deletion 
fragments (Figure 7E and data not shown) and identified the response element for the 
PPARγ:RXR (Figure 7F). We characterized the enhancer in reporter assays and also in 
electromobility shift assays (EMSA). The identified response element (Figure 7G), in 
consistence with the induction of the host gene, showed preferential response (Figure 7F) 
and binding to PPARγ (Figure 7H and I), which was due to its specific nucleotide 
sequence (Figure 7G). When we mutated the PPARγ binding site to the consensus 
AGGTCA we could detect the binding of PPARα, γ and δ as RXR heterodimers and also 
RXR homodimer (Supplementary Figure 10D). Interestingly, in the promoter of the 
mouse FABP4 another enhancer was described earlier {Tontonoz, 1994 #80}. In the 
human gene the homologue of this mouse enhancer was also responsive to PPAR 
activators very similarly to the newly described element (aP2 A refers to the newly 
identified element and aP2 PT refers to the homologue of the mouse enhancer) 
(Supplementary Figure 10A-C). 
Unexpectedly, we could detect the presence of a STAT6 binding site downstream to the 
newly identified enhancer (Figure 7G), which was not present around the other element 
(data not shown). This STAT6 response element was functional and as efficient as a 
known enhancer from the promoter of the eotaxin gene when tested in a reporter assay 
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(Figure 7C and D). A short promoter fragment that contained the composite element 
(both the newly described DR1 and the downstream STAT6 element) (Figure 7J) 
behaved similarly as the originally tested 5kb fragment (Figure 7A and B) indicating that 
this short DNA fragment contained all the required elements for the STAT6-augmented 
PPARγ response. Mutation of the STAT6 binding site in the composite element resulted 
in the annihilation of its responsiveness to IL-4 (Figure 7L) without effecting its 
induction by RSG. Mutation of the DR1 inhibited RSG-induced activation and 
interestingly almost completely eliminated the effects of IL-4 (Figure 7M). The newly 
described element clearly differed from the mouse homologue in its responsiveness to IL-
4: it did not show any response upon IL-4 (Figure 7K). 
We identified a composite response element in the promoter of the FABP4 containing a 
DR1 for PPARγ:RXR and another binding site for the STAT6. IL-4 could activate the 
transcription through the STAT6 element and could also improve PPARγ response 
through this element. These results indicate the requirement of DNA binding of the 
STAT6 to its response element to exert its effect on PPARγ. When isolated consensus 
DR1s (consensus or the one isolated from the enhancer of the FABP4) were tested 
STAT6 was not effective (Supplementary Figure 10E and F). Similarly, activity of Gal-
fusion PPARγ could not be augmented by STAT6 (Supplementary Figure 10G). 
With chromatin immunoprecipitation (ChIP) we could show the in vivo binding of 
PPARγ to the new composite element and also to the mouse homologue element (Figure 
8A and B). In consistence with our previous results STAT6 binding could be detected 
only on the new element (Figure 8C and D). 
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STAT6 interacts with PPARγ  
Since the two binding sites are in close proximity we sought to analyze if the two 
transcription factors could interact. First, we performed co-immunoprecipitation and we 
could detect the binding of STAT6 to PPARγ (Figure 8E and F). In order to characterize 
the interaction more intensively we performed pull-down experiments and STAT6 could 
be pulled down with resin-bound PPARγ (Figure 8G). We could detect interaction in the 
absence of IL-4 but IL-4 increased this interaction. 
By using various fragments of the STAT6 we could localize the interaction site to the 
XXX part of the STAT6. This is in agreement with or other results obtained from 
mammalian two-hybrid experiments (Supplementary Figure 11). We also analyzed the 
effects of these STAT6 fragments when transfected into 293T cells and analyzed which 
fragment could augment PPARγ responses (Supplementary Figure 11). 
Our results indicate that IL-4 augments PPARγ response via activation of STAT6, which 
consequently translocates to the nucleus binds to its response elements and interacts with 
PPARγ in order to improve its activity after ligand binding. With an unbiased method, 
using global gene expression profiling we showed that this phenomenon could work with 
most of the PPARγ-regulated genes (Figure 5A and B). However, to find and prove the 
exact molecular mechanism we characterized FABP4. We found a mechanism, which 
suggests that it might work in case of other target genes if response elements are present 
in the promoter of target genes. So, we used a bioinformatics approach to analyze the 
occurrence of STAT6 elements in the proximity of PPARγ binding sites. We could 
demonstrate that the incidence of STAT6 and also STAT1 response elements is higher in 
the neighborhood of PPARγ response elements (Figure 8H). 
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Discussion 
Estrogen receptor β inhibits ligand-induced PPARγ activity in adipocytes {Foryst-
Ludwig, 2008 #108}. 
Crosstalk: ERβ-PPARγ, LEPR-STATs, adipocyte-IL-4-PPARδ, PPARγ alternative 
activation Cell Metabolism by B. Steals {Bouhlel, 2007 #109} 
Disc.: The above model can be used only for conditions where PPARγ is considered 
mainly as a negative regulator of gene expression. However, it does not explain how the 
specificity of the liganded receptor can distinguish positive and negative regulation of 
transcription. 
We also determined the PPARγ-regulated genes and biological processes in the 
macrophages under the various inflammatory conditions. We performed analysis on 
multiple levels: 1. We studied PPARγ expression in various types of macrophages 2. We 
analyzed the activity of PPARγ on the level of the individual target genes. 3. With a 
systematic, non-biased approach we determined the global changes caused by PPARγ 
activation regarding the activation status of the macrophages. 
Analyzing the expression of PPARγ in various tissues we demonstrated that PPARγ is 
expressed mainly in the macrophages and its distribution shows an interesting pattern. 
Not every macrophage expresses PPARγ, but most of the macrophages carrying the 
alternative activation marker also have PPARγ. These highly PPARγ-positive cells are 
preferentially localized in the perifollicular areas of the lymphoid organs within the 
tissues and can be found in force at regions where macrophages first meet external 
stimuli (alveolar, perivascular, intestinal macrophages). 
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When we activated macrophages in vitro we found that PPARγ is not only induced upon 
alternative activation but also its activity is highly enhanced in the alternatively activated 
macrophages while classical activation decreases the level of the receptor and almost 
totally abolishes PPARγ-driven responses concerning both the positive and negative 
transcriptional events. 
We also identified the transcriptional targets of the receptor finding more upregulated 
than downregulated genes. Genes from either group belong dominantly to the alternative 
activation state. By analyzing PPARγ-regulated genes we determined the basic biological 
processes being modulated by the receptor and conclude that PPARγ influences two 
major programs: lipid metabolism and immune responses. 
With the data presented here it became important to study the inflammatory environment 
of macrophages and probably other cells when PPARγ is analyzed. Based on our work 
these conditions have dramatic effects on PPARγ activity, which should be addressed in 
future studies. 
It became also apparent from our results that PPARγ is a key transcription factor in the 
biology of alternatively activated macrophages. By inducing and activating the receptor 
IL-4 turns on PPARγ-regulated processes, which in turn will strengthen immunological 
changes IL-4 induced and also activate other types of responses e.g. lipid metabolism-
related ones that are not part of the IL-4-induced closely defined program. 
Our findings also suggest a new mechanism for the anti-inflammatory effects of the 
PPARγ: as a participant of the alternative activation program many anti-inflammatory 
effects ascribed to PPARγ may be due to its direct contribution to the transcriptional 
changes of alternative activation by which it shifts the macrophage from the classical 
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towards the alternative activation and as a part of this program several inflammatory 
genes are repressed directly or indirectly. PPARγ serves as a modulator of the alternative 
activation-induced transcriptional program by 1. further increasing many IL-4-induced 
genes and 2. inducing many genes repressed by classical activation which further 
enhances IL-4 dominance. 
Our present results indicate that the sequence of the various stimuli is of critical 
importance since pathogen-stimulated macrophages have no functional PPARγ so its 
agonists could hardly express receptor-dependent anti-inflammatory reactions while 
generation of IL-4 dominant environment and subsequent activation of the receptor is 
capable to inhibit inflammation by inducing its target genes. This hypothesis is supported 
by the findings of Alleva et al. who showed that treatment of murine macrophages with 
IFNγ prevented PPARγ activators from suppressing pro-inflammatory cytokines {Alleva, 
2002 #26}. We also claim that PPARγ is a predominantly positive regulator of 
transcription in human cells by inducing many genes being also induced during 
alternative activation or repressed during classical activation or being independent of 
activation. 
Our results throw new light upon the relation of PPARγ and LXR. Both PPARγ and LXR 
agonists expose anti-inflammatory effects {Joseph, 2003 #64}, both receptors are 
influenced by the inflammatory signals of the environment {Castrillo, 2003 #63}. In the 
human macrophages we found similar results as it was reported by Castrillo et al. 
{Castrillo, 2003 #63} in mouse macrophages: TLR3 (PolyI:C) and 4 (LPS) agonists but 
not TLR9 activators (CpG) inhibited LXR-induced target gene transcription and 
according to our findings all these signals inhibit PPARγ signaling as well. An interesting 
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observation is the opposite regulation of PPARγ and LXRα mRNAs upon inflammatory 
cytokines, which influence only PPARγ but not LXRα raising the possibility of a 
macrophage where PPARγ and LXRα signaling can be separated. The functional 
consequences of such a cell type are elusive and require further investigation. 
Upon these results we assign the spatiotemporal niche, namely the alternatively activated 
macrophages, for PPARγ in terms of the various inflammatory conditions of the 
macrophages throughout the body and also define the functional consequences of the 
active PPARγ by laying down the receptor-regulated biological programs. Our findings 
also identify PPARγ as a novel marker and functional participant of the alternative 
activation process in macrophages that regulated the transcription of many activation-
related genes. 
It was reported previously that IL-4 induced 12/15 lipoxygenase in murine macrophages 
that activated PPARγ by producing endogenous activators for the receptor {Huang, 1999 
#19}. To test this hypothesis in the human system we measured the expression of 15-
lipoxygenase and it is clear from our time course experiments that the IL-4 enhanced 
PPARγ activity is detectable much earlier than the lipoxygenase mRNA could be 
detected (data not shown). Therefore it is unlikely that the lipoxygenase pathway 
contributes to this enhanced activity at early time points. 
The role of Th2 cytokines in atherosclerosis is more controversial. Both Th1 and Th2 
responses are involved in the pathogenesis of atherosclerosis with a predominant role for 
the pro-inflammatory molecules in the pathogenesis {King, 2002 #73}{Davenport, 2003 
#72}. This is also supported by the observation that C57Black/6 mice (prone to Th1 
responses) can develop atherosclerosis while BALB/c mice (prone to Th2 immune 
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responses) are relatively resistant to atherogenesis {Paigen, 1985 #74}{Huber, 2001 
#75}. Targeted deletion of the transcription factor STAT6 through which IL-4 regulates 
gene expression in BALB/c mice makes them susceptible to atherogenesis {Huber, 2001 
#75}. 
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Experimental procedures 
 
Materials 
Cells were treated with the following ligands: AM580 (Biomol), LG268, a gift from R. 
Heyman (Ligand Pharmaceuticals), Wy14643, Rosiglitazone (Rosigl.), T0901317 (Alexis 
Biochemicals), GW501516 and GW9662 were gifts from T. M. Willson 
(GlaxoSmithKline), oxidized LDL and diI-oxidized LDL (Intracel). Cytokines were 
obtained from Peprotech. All other reagents were obtained from Sigma or as indicated. 
 
Flow cytometry 
Analysis of cell surface expression of proteins was performed on a Beckton Dickinson 
FACSCalibur Flow Cytometer. Briefly, cells were washed in PBS (phosphate buffered 
saline) pH7.4 supplemented with 0.5% (BSA) bovine serum albumin then were incubated 
with antiCD14-PE, antiCD86-PE, antiCD23-PE, anti-mannose receptor-PE, antiDC-
SIGN-FITC, anti HLA-DR-PE, antiCD1a-PE or isotype control (Beckton-Dickinson) 
antibody, respectively for 1 hour at 4oC, finally cells were washed in PBS-BSA and 
10000 cells were counted on the cytometer. 
 
Immunohistochemistry 
For immunocytochemistry macrophages (6x106 cells/group) were pelleted and fixed in 
4% paraformaldehyde (pH 7.3) for 24 h at 4oC. Cell blocks were then embedded in 
paraffin followed by serial sectionings (4 µm thick). After deparaffinisation and 
dehydration, serial sections from each cell group, mounted on the same glass slides, were 
 39 
used for peroxidase-based indirect immunohistochemistry (IHC). Briefly, sections were 
treated with 3% H2O2 in methanol for 15 min at room temperature to block the 
endogenous peroxidase. For antigen unmasking, sections were heated in antigen 
retrieving citrate buffer (pH 6.0, Dako) for 2 min at 120oC using a pressure cooker. 
Immunostainings of cells for PPARγ were carried out using the biotin-free Catalyzed 
Signal Amplification IHC detection kit according to the manufacturer's instructions 
(CSAII, Dako,). After blocking the non-specific binding sites, sections were incubated 
with the primary antibodies for 1 h at room temperature prior to use the biotinylated 
secondary antibodies. The peroxidase-mediated color development was set up for 5 min 
using the VIP substrate (Vector Labs). Finally, the sections were counterstained with 
methylgreen. Immunofluorescence (IF) stainings were carried out on normal human 
tissues obtained from the formalin-fixed and paraffin-embedded surgical specimen 
archives of the Department of Pathology, University of Debrecen. Following the 
incubations with the primary then the horse-radish peroxidase (HRP) conjugated 
secondary goat anti-mouse antibodies, IF for PPARγ staining was carried out using the 
tetramethyl-rhodamine (TMR)-tagged tyramide reagent of the fluorescent amplification 
kit according to the manufacturer's instructions. All other IF stainings (CD68, DC-SIGN) 
were made using biotinilated secondary antibodies and streptavidin-FITC. For double IF, 
sequential immunostainings were used. Briefly, following the red fluorescence TMR 
development for PPARγ staining, the second primary antibodies were applied and then 
developed with FITC (green fluorescence) using the fluorescent ABC kit. After rinsing, 
the sections were counterstained with 4',6-diamidino-2-phenylindole (DAPI) (blue 
nuclear fluorescence). Fluorescent microphotographs were made with single exposure 
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using excitation filter to visualize simultaneously both green (FITC) and red (TMR) 
together with the blue (DAPI) fluorescence lights. 
 
Isolation and culture of human monocytes and stem cells 
Human monocytes were isolated from healthy volunteer’s buffy coat obtained from the 
Regional Blood Bank. Monocyte separation was carried out according to the 
manufacturer’s instructions using CD14 MicroBeads (Miltenyi Biotec). Monocytes were 
differentiated for the indicated time. Cells were cultured in RPMI 1640 supplemented 
with 10% FBS, 2mM glutamine, penicillin and streptomycin and treated with vehicle 
(ethanol:dimethyl-sulfoxide 1:1) or as indicated. For the activation we used IL-4 (100 
ng/ml), IFNγ (100 ng/ml) and TNFα (50 ng/ml), IL-13 (100 ng/ml), Dexamethasone (2.5 
µM), E. coli (O55:B5 serotype) LPS (100 ng/ml), E. coli Lipid A (50 µg/ml), CpG (100 
nM), Polyinsinic-polycitydilic acid (PolyI:C) (5 µg/ml), S. aureus lipoteichoic acid 
(LTA) (5 µg/ml) or L. monocytogenes (ATCC 43251) at a MOI (multiplicity of infection) 
of 10. 
Human CD34 positive stem cells were isolated with CliniMax (AmCell GmbH, Bergisch 
Gladbach, Germany) from peripheral blood of granulocyte colony stimulating factor-
treated patients according to the protocol. Stem cells were expanded with recombinant 
human Flt-3L (25 ng/ml), stem cell factor (20 ng/ml), IL-6 (20 ng/ml) and IL-3 (20 
ng/ml) for 10 days and then differentiated to macrophages with recombinant human M-
CSF (10 ng/ml) for 8 days. 
 
RNA isolation and real-time quantitative RT PCR 
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Total RNA was isolated from cells using Trizol Reagent (Invitrogen) according to the 
instructions. RNA was transcribed into cDNA via random hexamer priming using 
SuperScript II (Invitrogen) reverse transcriptase. Transcript quantification was performed 
by quantitative real-time RT (reverse transcriptase) PCR (polymerase chain reaction) 
using Taqman probes (self-made assays) or Taqman Gene Expression Assays (Applied 
Biosystems). Transcript levels were normalized to the level of cyclophilin D. Sequences 
of primers and Taqman probes or Taqman Assays IDs used in transcript quantification 
are listed in Supplemental Table 1. 
For the validation of the microarray data we used Taqman Low Density Arrays (TLDA). 
The Assay IDs are listed in Supplemental Table 2. For these experiments RNA samples 
were transcribed with High Capacity cDNA Archive Kit (Applied Biosystems). 
 
Western blotting 
Cells were treated for two days as indicated and were washed in PBS then lysed in buffer 
A (Tris-HCl pH7.5, 1mM EDTA, 15mM β-mercaptoethanol, 0.1% Triton X 100, 0.5mM 
PMSF (phenyl-methyl-sulfonyl fluoride). 25µg total protein was separated on 10% SDS-
PAGE (polyacrylamid gel electrophoresis) and transferred to PVDF membrane (Bio-Rad 
Laboratories). After blocking with 5% dry milk the membrane was probed with anti-
FABP4 antibody (Cayman Chemical Company) or anti-GAPDH (glyceraldehyde-3-
phosphate-dehydrogenase) antibody (Abcam) and subsequently with peroxidase-
conjugated secondary antibody. ECL detection kit (Pierce) was used for signal detection. 
 
Mice 
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Mice carrying null or floxed alleles of Pparγ were created as described previously 
{Barak, 1999 #4}, {Miles, 2000 #56}, {Hevener, 2003 #57}. These mice were 
backcrossed to the C57BL/6J strain for eight generations. Mice were bred with 
Lysozyme-Cre (Lys-Cre) transgene animals to create the following genotypes: Pparγ+/+ 
Lys-Cre, Pparγfl/fl Lys-Cre, Pparγ+/- Lys-Cre and Pparγfl/- Lys-Cre. Genotypes were 
determined by PCR of tail DNA. PCR genotyping was carried out by using the following 
primers: for the Cre transgene, 5'-GCATTACCGGTCGATGCAACGAGTG-3' and 5'-
GAACGCTAGAGCCTGTTTTGCACGTTC-3'; for the upstream loxP site, 5'-
CTAGTGAAGTATACTATACTCTGTGCAGCC-3' and 5'-
GTGTCATAATAAACATGGGAGCATAGAAGC-3'; and for the null allel, 5'-
AGGCCACCATGGAAAGCCACAGTTCCTC-3' and 5'-
GCTGGCGAAAGGGGGATGTGCTGCAAG-3'. Genomic DNA was amplified by 35 
cycles of 94oC for 20 s, 60oC for 30 s, and 72oC for 55 s.  
RT PCR was performed with SuperScript II (Invitrogen). Sense (5'-
GTCACGTTCTGACAGGACTGTGTGAC-3') and antisense (5'-
TATCACTGGAGATCTCCGCCAACAGC-3') primers were designed to anneal to 
regions in exons A1 and 4 of PPAR1, respectively, which distinguish the full-length (700-
bp) and recombined (300-bp) transcripts {He, 2003 #58}. PCR was performed by 40 
cycles of 94oC for 20 s, 60oC for 30 s, and 72oC for 60 s. Lysozyme-Cre animals were 
obtained from I. Förster (University of Munich) {Clausen, 1999 #61}. All animal 
experiments were carried out under ethical guidelines, which were established by the 28th 
Act in 1998 of the Parliament of the Republic of Hungary. Animals were housed under 
minimal disease (MD) conditions in a laboratory animal facility seeing the requirements 
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of FELASA recommendations and DIN EN ISO 9001 standards. Animal boxes were 
ventilated with HEPA filtered air, animals received sterilized pellet diet (Altromin) and 
tap water (ad libitum). The cages contained sterilized bedding material.  The room 
lightning was automatically switched on at 6:00 and off at 18:00. The room temperature 
was 20± 2 °C, the relative humidity was 50%.  
 
Isolation and culturing of mouse peritoneal and bone marrow cells 
Thioglycolate-elicited macrophages were harvested from the peritoneal cavity 4 days 
after injection of 3 ml 3% thioglycolate solution. Cells were washed in saline and 
cultured in RPMI 1640 supplemented with 10% FBS, 2mM glutamine, penicillin and 
streptomycin for two days. Bone marrow cells were isolated from the femur of mice then 
were washed in saline then cultured in RPMI 1640 supplemented with 10% FBS, 2mM 
glutamine, penicillin and streptomycin. These cells were differentiated to macrophages 
by M-CSF (20 ng/ml) or to dendritic cells by GM-CSF (20 ng/ml) and IL-4 (20 ng/ml) 
for 10 days. For activation of macrophages similar methods were used as in the human 
macrophages: IL-4 (20 ng/ml), IFNγ (100 ng/ml), TNFα (20ng/ml), E. coli (O55:B5 
serotype) LPS (100 ng/ml). Fresh medium containing cytokines and ligands were added 
every third day to complement the old medium. 
 
Microarray analysis 
Total RNA was isolated using RNeasy kit (Qiagen). cRNA was generated from 5 µg of 
total RNA by using the SuperScript Choice Kit (Invitrogen) and the High Yield RNA 
transcription labeling kit (Enzo Diagnostics). Fragmented cRNA was hybridized to 
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Affymetrix (Santa Clara, CA) arrays (Human Genome U133 Plus 2.0) according to 
Affymetrix standard protocols. Analysis was performed using GeneSpring 7.2 (Agilent). 
The Affymetrix .cel files were loaded into GeneSpring and analyzed by GC-RMA. 3 
biological replicates (3 for each condition, non-activated, alternatively activated and 
classically activated plus/minus Rosigl. treated) of the 12h treated samples were analyzed 
together as replicates. After a per chip normalization to the 50th percentile of expression 
values obtained from the whole array we performed per gene normalization to the median 
expression of the given gene during the various conditions and finally each chip were 
normalized to its specific vehicle-treated control. After determining the changing genes 
based on a T-test (parametric, variances assumed to be equal, using Benjamini and 
Hochberg false discovery rate as multiple testing correction), p-value cutoff 0.05 we 
selected those genes that showed at least 1.5 fold changes. For the validation on the 
TLDA we chose changing genes based on two independent analyses. We reanalyzed the 
original microarray data with MAS 5 algorithm and determined the changing changes in 
a similar manner as with the GC-RMA and selected genes that showed significant 
changes upon Rosigl. treatment with both methods. 4 replicates of a 6h long Rosigl. 
treatment of alternatively activated macrophages were also analyzed similarly and based 
on these data we completed the list of genes selected for validation. Activation-specific 
changes were analyzed similarly. TLDA results were analyzed in a similar manner as the 
microarray data. We loaded the raw Ct values obtained in the real-time Q-PCR runs into 
GeneSpring and handled as Q-PCR data. For normalization we chose three methods: first 
we normalized to the housekeeping gene cyclophilin D, second to another housekeeping 
gene, 36B4 and third we performed a global scaling by normalizing everything to the 
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median expression of all measured transcripts. We went through the analysis as described 
above and took those genes that showed significant changes in at least two normalization 
methods. 
 
Statistical tests 
All data are presented as means ±SD. In real-time quantitative PCR the mean and 
standard deviation were calculated for both the normalized and the normalizer values. To 
incorporate the random errors of the measurements we used the propagation of errors to 
determine the standard deviation of the normalized values. For all experiments we made 
at least four biological replicates and on the fold changes we performed an F test 
followed by an unpaired (two tail) t test and results were considered significant with 
p<0.01. 
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